Loading...

SONN SONNET BIOTHERAPEUTICS HOLDINGS INC Product Launches 8-K Filing

SNNT

SNN

SONNET BIOTHERAPEUTICS HOLDINGS INC

(SONN)

2025 8-K

Show Summary

Show Summary

Convertible Notes Sale

Voluntary Delisting

Clinical Trial Update

Management Changes

Clinical Trial Update

Patent Approval

Data Presentation

ADC Platform Launch

Financial Results

Trial Expansion

Financial Results

Equity Offering

SON-1010 Trial Results

Drug Development Update

Public Offering

Patent Issuance

Nasdaq Compliance

License Agreement

Clinical Trial Update

Annual Meeting Results

Investor Presentation

Clinical Collaboration

Financial Results

Clinical Trial Data Announc...

Entry Into a Material Defin...

Product Launches

Exploring Strategic Alterna...

Clinical Data Update

Financial Results Press Rel...

Equity Facility Agreement

Phase 1b/2a clinical trial ...

Disinvestment of Assets

Financial Results for Q4 2023

Notice from Nasdaq

Sale of New Jersey Net Oper...

Departure of Directors or C...

Delisting Notice

Financial Results for Fisca...

Compliance regained with Na...

Reverse Stock Split

Annual Meeting Results

Letter to Stockholders

Financial Results for Q2 2023

Investor Meetings

Securities Purchase Agreement

Financial Results Press Rel...

Phase 1 Clinical Trials Update

Regulation FD Disclosure

Financial Results for Q4 2022

Public Offering

Clinical Collaboration Agre...

External Links:

On March 26, 2025, Sonnet Biotherapeutics announced positive safety findings from the Phase 1 SB101 clinical trial of SON-1010 in combination with trabectedin for advanced leiomyosarcoma or liposarcoma, with 54% of patients showing clinical benefit from SON-1010 monotherapy.

AI Assistant

SONNET BIOTHERAPEUTICS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.